© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 8, 702-708,
April 21, 1999
© 1999 Oxford University Press
REPORTS |
Screening for Breast Cancer: Time, Travel, and Out-of-Pocket Expenses
Affiliations of authors: R. H. Secker-Walker, G. J. Hooper (Office of Health Promotion Research), P. M. Vacek (Biometry Facility), D. A. Plante (Department of Medicine), University of Vermont, Burlington; A. S. Detsky, Department of Medicine, Mount Sinai Hospital, Toronto, ON, Canada.
Correspondence to: Roger H. Secker-Walker, M.D., 1 South Prospect St., Burlington, VT 05401-3444 (e-mail: rseckerw{at}zoo.uvm.edu).
BACKGROUND: We estimated the personal costs to women found to have a breast problem (either breast cancer or benign breast disease) in terms of time spent, miles traveled, and cash payments made for detection, diagnosis, initial treatment, and follow-up. METHODS: We analyzed data from personal interviews with 465 women from four communities in Florida. These women were randomly selected from those with a recent breast biopsy (within 6-8 months) that indicated either breast cancer (208 women) or benign breast disease (257 women). One community was the site of a multifaceted intervention to promote breast screening, and the other three communities were comparison sites for evaluation of that intervention. All P values are two-sided. RESULTS: In comparison with time spent and travel distance for women with benign breast disease (13 hours away from home and 56 miles traveled), time spent and travel distance were statistically significantly higher (P<.001) for treatment and follow-up of women with breast cancer (89 hours and 369 miles). Personal financial costs for treatment of women with breast cancer were also statistically significantly higher (breast cancer = $604; benign breast disease = $76; P <.001) but were statistically significantly lower for detection and diagnosis (breast cancer = $170; benign breast disease = $310; P<.001). Among women with breast cancer, time spent for treatment was statistically significantly lower (P = .013) when their breast cancer was detected by screening (68.9 hours) than when it was detected because of symptoms (84.2 hours). Personal cash payments for detection, diagnosis, and treatment were statistically significantly lower among women whose breast problems were detected by screening than among women whose breast problems were detected because of symptoms (screening detected = $453; symptom detected = $749; P = .045). CONCLUSION: There are substantial personal costs for women who are found to have a breast problem, whether the costs are associated with problems identified through screening or because of symptoms.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. E. Jonas, L. B. Russell, R. S. Sandler, J. Chou, and M. Pignone Value of Patient Time Invested in the Colonoscopy Screening Process: Time Requirements for Colonoscopy Study Med Decis Making, February 1, 2008; 28(1): 56 - 65. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Dawood, K. Broglio, A. M. Gonzalez-Angulo, S.-W. Kau, W. Yang, C. Albarracin, F. Meric, G. Hortobagyi, and R. Theriault Development of New Cancers in Patients with DCIS: The M.D. Anderson Experience Ann. Surg. Oncol., January 1, 2008; 15(1): 244 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Sumner III, L. G. Koniaris, S. E. Snell, S. Spector, J. Powell, E. Avisar, F. Moffat, A. S. Livingstone, and D. Franceschi Results of 23,810 Cases of Ductal Carcinoma-in-situ Ann. Surg. Oncol., May 1, 2007; 14(5): 1638 - 1643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Anderson, J. S. Jacobson, D. F. Heitjan, J. G. Zivin, D. Hershman, A. I. Neugut, and V. R. Grann Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med, March 21, 2006; 144(6): 397 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mandelblatt, C. Armetta, K. R. Yabroff, W. Liang, and W. Lawrence Descriptive Review of the Literature on Breast Cancer Outcomes: 1990 Through 2000 J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 8 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Mandelblatt, C. B. Schechter, K. R. Yabroff, W. Lawrence, J. Dignam, P. Muennig, Y. Chavez, J. Cullen, and M. Fahs Benefits and Costs of Interventions to Improve Breast Cancer Outcomes in African American Women J. Clin. Oncol., July 1, 2004; 22(13): 2554 - 2566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hershman, V. Sundararajan, J. S. Jacobson, D. F. Heitjan, A. I. Neugut, and V. R. Grann Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness Analysis J. Clin. Oncol., January 1, 2002; 20(1): 9 - 16. [Abstract] [Full Text] [PDF]
|
|